GlobalSCAPE (GSB), Sinovac (SVA), Q3 Strong Financial Perfor

GlobalSCAPE, Inc. (NYSE MKT:GSB)

After closing bell on Tuesday's trading session, GSB reported strong earnings growth on its financial results, driven by increased revenue combined with lower operating expenses.

For the third quarter 2013, GSB posted revenue of $6.3 million, a 3% increase year over year, and net income of $2.3 million or $0.12 per share, compared to a net loss of $2.7 million, or ($0.15) per share, in the same period the prior year.

GSB ensures the reliability of mission-critical operations by securing sensitive data and intellectual property. GSB ’s suite of solutions features EFT Server, the industry-leading enterprise file transfer solution that delivers military-grade security and a customizable platform for achieving best in class control and visibility of data in motion or at rest, across multiple locations.

More about GlobalSCAPE, Inc. GlobalSCAPE, Inc. (NYSE MKT:GSB) at www.globalscape.com

**

Crown Equity Holdings Inc. (CRWE)

Looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, CRWE is targeting the multi-billion dollar online video-sharing market.

Online video is proving to be a powerful marketing tool for many businesses. Video has moved from a ‘nice to have’ to a ‘must have’. Indeed, if a business is not doing video, they are now behind the competition, according to Sage Lewis, a leading Digital Marketing expert in a recent seminar.

Strategic plans are being developed for CRWE ’s Division CRWETube ( www.crwetube.com )

As a worldwide online multi-media publisher, CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. The company launches, invests and manages select businesses, projects and real estate endeavors.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

**

Sinovac Biotech Ltd. (Nasdaq:SVA)

SVA reported on its unaudited financial results another strong quarter with revenue growth, which resulted in another profitable quarter on a sequential quarterly basis.

For the third quarter 2013, SVA posted total sales of $22.1 million, a 54.5% increase year over year, gross profit of $15.9 million, a 111.7% increase compared to the same period the prior year, and net income attributable to common stockholders of $2.3 million, or $0.04 per basic and diluted share, compared to net loss of $3.0 million, or ($0.05) per basic and diluted share in the third quarter 2012.

SVA is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and mumps, as well as animal rabies vaccine for canines.

More about Sinovac Biotech Ltd. (Nasdaq:SVA) at www.sinovac.com

**

Read Full Disclaimer at www.pennyomega.com/disclaimer